In Myasthenia Gravis (MG), nerve impulse transmission is interrupted at the neuromuscular junction, where nerve cells and muscles connect due to antibodies blocking or destroying acetylcholine receptors. Acetylcholine receptors activate muscle contractions; thus, their destruction prevents those contractions from occurring.
A recent article published in the Virology Journal outlined what is currently known about COVID-19 infection and treatments in autoimmune disease patients, including specific diseases which pose a higher risk of infection, disease severity and hospitalization.
Read More »To better understand the effect of a SARS-CoV-2 infection in patients living with Myasthenia Gravis, researchers analyzed 83 Myasthenia Gravis patients who tested positive for COVID-19.
Read More »Symptoms related to COVID-19 infections such as systemic inflammation, neurological complications, and a dysregulated immune response can lead to worse clinical outcomes for patients with Myasthenia Gravis (MG). Researchers conducted an observational retrospective study to measure COVID-19 outcomes in these patients, especially in regard to exacerbation of MG symptoms.
Read More »Autoimmune disease is currently considered a risk factor for severe COVID-19. A research article published in Rheumatology last Fall summarized 30-day outcomes of autoimmune disease (AD) patients following hospitalization with COVID-19. AD patients diagnosed and/or hospitalized between January and June 2020 with COVID-19 were included, and their 30 day outcomes were compared to patients with at least one AD hospitalized with influenza from September 2017 through April 2018.
Read More »